Skip to main content

Table 1 Characteristics of 64 relapsed case subjects and 64 successfully treated matched control subjects with acute lymphoblastic leukemia selected from trials ALL-BFM 86 and ALL-BFM 90

From: Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy

 

Cases (%)

Controls (%)

Trial

  

   ALL-BFM 86

35 (54.7)

35 (54.7)

   ALL-BFM 90

29 (45.3)

29 (45.3)

Sex

  

   Male

42 (65.6)

42 (65.6)

   Female

22 (34.4)

22 (34.4)

Age (y)

  

   <1

1 (1.6)

1 (1.6)

   1-9

56 (87.5)

56 (87.5)

   10-14

6 (9.4)

7 (10.9)

   15-18

1 (1.6)

-

WBCa (103/μl)

  

   <10

42 (65.6)

41 (64.1)

   10-<50

21 (32.8)

22 (34.4)

   ≥ 50

1 (1.6)

1 (1.6)

Immunophenotype

  

   c-ALLb

54 (84.4)

54 (84.4)

   pre-B-ALLc

10 (15.6)

10 (15.6)

Risk groupd

  

   standard

23 (35.9)

23 (35.9)

   intermediate

41 (64.1)

41 (64.1)

   high

-

-

DNA indexe

  

   <1.16

30 (46.9)

30 (46.9)

   ≥ 1.16

12 (18.8)

7 (10.9)

   not examined

22 (34.4)

27 (42.2)

Genotype

  

   normal

4 (6.3)

10 (15.6)

   11q23 abberations

-

1 (1.6)

   t(1;19)

1 (1.6)

-

   t(9;22)

-

-

   other

15 (23.3)

13 (20.3)

   not examined

44 (68.8)

40 (62.5)

  1. a white blood cell count b common acute lymphoblastic leukemia c precursor B-cell acute lymphoblastic leukemia d therapy stratification in risk groups was mainly based on initial leukemic cell mass estimate and initial treatment response [1618], e ratio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes